Insights
Search Results
Client Highlights
4.08.26
Wilson Sonsini Advises Sidewinder Therapeutics on Oversubscribed $137 Million Series B Financing
On April 8, 2026, Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific antibody-drug conjugates (ADCs) for the treatment of cancer, announced the closing of an oversubscribed $137 million Series B financing. The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from the sole Series A investor OrbiMed, as well as new investors including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati advised Sidewinder Therapeutics on the transaction.
Client Highlights
4.01.26
Wilson Sonsini Advises Ambrosia Biosciences on $100 Million Oversubscribed Series B Financing
On March 31, 2026, Ambrosia Biosciences, Inc., a privately held drug discovery company, announced a $100 million oversubscribed Series B preferred stock financing. The round was co-led by new investors Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital. Existing investors BVF Partners and Boulder Ventures also participated, and were joined by additional new investors. Wilson Sonsini Goodrich & Rosati advised Ambrosia Biosciences on the transaction.
Client Highlights
12.15.25
Wilson Sonsini Advises Tenaya Therapeutics on Pricing of Public Offering
On December 11, 2025, Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop, and deliver potentially curative therapies that address the underlying causes of heart disease, announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses. Wilson Sonsini Goodrich & Rosati advised Tenaya on the transaction.
Client Highlights
6.18.25
Firm Advises Enliven Therapeutics on $230 Million Public Offering
On June 16, 2025, Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, announced the close of its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,526,250 additional shares of its common stock, at a price to the public of $19.66 per share and pre-funded warrants to purchase 1,780,263 shares of its common stock at a price to the public of $19.659 per pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven. The gross proceeds from the offering were approximately $230 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Enliven on the offering.
Client Highlights
5.06.25
Wilson Sonsini Advises Stately Bio on $12 Million Seed Financing
On May 2, 2025, Stately Bio, a start-up developing cell therapies using an ML-powered live-cell imaging platform, emerged from stealth with $12 million in seed financing. The funding was led by AIX Ventures, with participation from Dimension Capital, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui Global Investment, BoxOne Ventures, Axial VC, Jeff Dean (Chief Scientist at Google DeepMind), Jeremy Wertheimer (co-founder of ITA Software), and Tom Berry (co-founder of Carbon Health). The new funding will be used to scale the company’s platform technology and mature its internal pipeline of stem cell-derived therapeutics.
Client Highlights
4.23.25
Wilson Sonsini Advises Synthetic Design Lab on $20 Million Seed Funding
On April 23, 2025, Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic platform against a range of cancer indications, emerged from stealth with $20 million in seed financing. Playground Global and Godfrey Capital were among the investors in the funding round.
Client Highlights
12.10.24
Wilson Sonsini Advises Ambrosia Biosciences on $25 Million Series A
On December 10, 2024, Ambrosia Biosciences, a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders, announced the successful second closing of its Series A financing. This closing was led by Merck with additional participation from existing investors BVF Partners and Boulder Ventures. Wilson Sonsini Goodrich & Rosati advised Ambrosia Biosciences on the transaction.
Client Highlights
4.23.24
Wilson Sonsini Advises Rubedo on $40M Series A Financing
On April 22, 2024, Rubedo Life Sciences, a Sunnyvale, CA-based biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells that drive age-related diseases, closed a $40M Series A financing round. The round was led by Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, Italian Angels for Growth (IAG), and other investors. Wilson Sonsini Goodrich & Rosati advised Rubedo on the transaction.
Client Highlights
4.03.24
Wilson Sonsini Advises Alterome on $132 Million Series B
On April 3, 2024, Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, announced the closing of a $132 million Series B financing. The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures. Wilson Sonsini Goodrich & Rosati advised Alterome on the transaction.
Client Highlights
2.15.24
Wilson Sonsini Advises Firefly Bio on $94 Million Series A
On February 15, 2024, California-based Firefly Bio, a company dedicated to advance Degrader Antibody Conjugates (DACs) to treat cancer, emerged from stealth and successfully completed a $94 million Series A financing found. Founding investor Versant Ventures and MPM BioImpact co-led the round alongside Decheng Capital and with participation from Eli Lilly & Company. Wilson Sonsini Goodrich & Rosati advised Firefly Bio on the transaction.
Client Highlights
2.13.24
Wilson Sonsini Advises Sana Biotechnology on Upsized Follow-On Offering
On February 12, 2024, Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, announced the closing of its previously announced underwritten public offering for total gross proceeds of approximately $189.75 million. Wilson Sonsini Goodrich & Rosati advised Sana Biotechnology on the transaction.
Client Highlights
10.11.23
Wilson Sonsini Advises Cleanlab on $25 Million Series A Funding
On October 10, 2023, Cleanlab, the company behind the automated data curation solution used to increase the dollar value of every data point in enterprise artificial intelligence (AI), large language model (LLM), and analytics solutions, closed $25 million in a Series A financing round co-led by Menlo Ventures and TQ Ventures. Existing investor Bain Capital Ventures (BCV) and new investor Databricks Ventures participated in this funding round, bringing Cleanlab’s total funding to $30 million.